VCI Wealth Management LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 92,105 shares of the company's stock, valued at approximately $1,627,000.
Several other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Kenvue in the 2nd quarter worth approximately $2,882,279,000. Pentwater Capital Management LP purchased a new position in shares of Kenvue during the 2nd quarter valued at approximately $977,094,000. HBK Investments L P increased its holdings in shares of Kenvue by 33.3% during the 2nd quarter. HBK Investments L P now owns 28,000,001 shares of the company's stock valued at $535,080,000 after purchasing an additional 7,000,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Kenvue by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company's stock valued at $383,938,000 after purchasing an additional 196,981 shares in the last quarter. Finally, Amundi lifted its stake in shares of Kenvue by 41.2% in the 2nd quarter. Amundi now owns 18,483,326 shares of the company's stock valued at $353,216,000 after purchasing an additional 5,392,413 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Stock Up 0.5%
Shares of KVUE opened at $19.41 on Tuesday. The firm has a market cap of $37.28 billion, a P/E ratio of 16.38, a PEG ratio of 1.77 and a beta of 0.48. Kenvue Inc. has a 12 month low of $14.06 and a 12 month high of $20.13. The stock's 50 day moving average is $18.41 and its two-hundred day moving average is $18.20. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, hitting the consensus estimate of $0.29. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The business's quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. Analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. Kenvue's dividend payout ratio (DPR) is currently 95.45%.
Analyst Ratings Changes
KVUE has been the topic of a number of recent analyst reports. Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. UBS Group lifted their price objective on shares of Kenvue from $19.00 to $20.00 and gave the company a "neutral" rating in a report on Monday. Wall Street Zen cut shares of Kenvue from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. HSBC decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Finally, Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 21st. Twelve equities research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $19.44.
Read Our Latest Stock Report on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.
The company's brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson's and OGX in oral care, baby care and hair care.
See Also
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.